Currently submitted to: JMIR Formative Research
Date Submitted: Mar 8, 2026
Open Peer Review Period: Mar 9, 2026 - May 4, 2026
(currently open for review)
Warning: This is an author submission that is not peer-reviewed or edited. Preprints - unless they show as "accepted" - should not be relied on to guide clinical practice or health-related behavior and should not be reported in news media as established information.
The efficacy of advanced hybrid closed-loop insulin delivery system in Asian patients with type 1 diabetes – a pilot study
ABSTRACT
Background:
MiniMed 780G insulin delivery system has demonstrated improved HbA1c, time-in-range (TIR) and quality of life (QoL) in clinical trials but real-world studies are lacking in Southeast Asia.
Objective:
Our study aims to evaluate the efficacy, safety and the impact on QoL of MiniMed 780G in adults with type 1 diabetes (T1D) over 24 weeks.
Methods:
A prospective, single centre pilot study was conducted in patients with T1D on multiple daily injections or conventional pump therapy. Primary endpoints include the change in HbA1c at 12 and 24 weeks. Secondary endpoints include CGM glycaemic metrics, total daily insulin dose (TDD), quality of life (QoL) scores and adverse events.
Results:
9 patients (5 males) with a mean age of 35 ± 10.9 years completed the study. Mean HbA1c improved from 7.3% (56.3 mmol/mol) to 6.9% (51.2 mmol/mol) at 12 weeks and 7% (53.0 mmol/mol) at 24 weeks respectively. All patients achieved the target TIR of >70%, TAR of <25% and TBR of <4% at 12 and 24 weeks. Reduction in TDD were observed for all patients.
Conclusions:
Our study demonstrated the usability, safety and consistency of MiniMed 780G in improving glycaemic outcomes in Asian adults with T1D independent of their baseline insulin therapies. Clinical Trial: Not applicable
Citation
Request queued. Please wait while the file is being generated. It may take some time.
Copyright
© The authors. All rights reserved. This is a privileged document currently under peer-review/community review (or an accepted/rejected manuscript). Authors have provided JMIR Publications with an exclusive license to publish this preprint on it's website for review and ahead-of-print citation purposes only. While the final peer-reviewed paper may be licensed under a cc-by license on publication, at this stage authors and publisher expressively prohibit redistribution of this draft paper other than for review purposes.